A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

By A. Huang, Bernardo García-Carreras, M. Hitchings, Bingyi Yang, L. Katzelnick, S. Rattigan, Brooke A. Borgert, Carlos A Moreno, B. Solomon, Luke Trimmer-Smith and 7 more. 2020

724 citations recorded by the source corpus.

Many public health responses and modeled scenarios for COVID-19 outbreaks caused by SARS-CoV-2 assume that infection results in an immune response that protects individuals from future infections or illness for some amount of time. The presence or absence of protective immunity due to infection or vaccination (when available) will affect future transmission and illness severity. Here, we review the scientific literature on antibody immunity to coronaviruses, including SARS-CoV-2 as well as the related SARS-CoV, MERS-CoV and endemic human coronaviruses (HCoVs). We reviewed 2,452 abstracts and identified 491 manuscripts relevant to 5 areas of focus: 1) antibody kinetics, 2) correlates of protection, 3) immunopathogenesis, 4) antigenic diversity and cross-reactivity, and 5) population seroprevalence. While further studies of SARS-CoV-2 are necessary to determine immune responses, evidence from other coronaviruses can provide clues and guide future research. Antibody mediated immunity to SARS-CoV-2 will affect future transmission and disease severity. This systematic review on antibody response to coronaviruses, including SARS-CoV-2, SARS-CoV, MERS-CoV and endemic coronaviruses provides insights into kinetics, correlates of protection, and association with disease severity.

Subfields: Infectious Diseases

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. K. Ng
2. N. O'Reilly
3. S. Gandhi
4. H. Peckham
5. P. Walker
6. Charles Swanton
7. Annachiara Rosa
8. William Bolland

Citations in the corpus

• Preexisting and de novo humoral immunity to SARS-CoV-2 in humans (2020, background): “characteristic age distribution, being the highest in children and adolescents (1, 4-8).”
• Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals (2020, neutral): “All donors were IgG seropositive to HCoV-OC43 and HCoV-NL63 RBD, to varying degrees (Figure 5C), consistent with the endemic nature of these viruses (Gorse et al., 2010; Huang et al., 2020; Severance et al., 2008).”